Cargando…

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

OBJECTIVES: To investigate whether bortezomib, a proteasome inhibitor approved for treatment of multiple myeloma, induces clinically relevant plasma cell (PC) depletion in patients with active, refractory systemic lupus erythematosus (SLE). METHODS: Twelve patients received a median of two (range 1–...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alexander, Tobias, Sarfert, Ramona, Klotsche, Jens, Kühl, Anja A, Rubbert-Roth, Andrea, Lorenz, Hannes-Martin, Rech, Jürgen, Hoyer, Bimba F, Cheng, Qingyu, Waka, Aderajew, Taddeo, Adriano, Wiesener, Michael, Schett, Georg, Burmester, Gerd-Rüdiger, Radbruch, Andreas, Hiepe, Falk, Voll, Reinhard E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Basic and Translational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484251/ https://www.ncbi.nlm.nih.gov/pubmed/25710470 http://dx.doi.org/10.1136/annrheumdis-2014-206016

Ejemplares similares

Therapeutic inhibition of proteasomes in systemic lupus erythematosus
por: Hiepe, Falk, et al.
Publicado: (2011)

Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice
por: Khodadadi, Laleh, et al.
Publicado: (2015)

Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors
por: Taddeo, Adriano, et al.
Publicado: (2015)

Pathogenic memory plasma cells in autoimmunity
por: Chang, Hyun-Dong, et al.
Publicado: (2019)

Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus
por: Mahler, Michael, et al.
Publicado: (2007)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Short-lived Plasmablasts and Long-lived Plasma Cells Contribute to Chronic Humoral Autoimmunity in NZB/W Mice
por: Hoyer, Bimba F., et al.
Publicado: (2004)

Impact of cellular therapies on autoreactive, long-lived plasma cells in autoimmune diseases (AID)
por: Hiepe, F, et al.
Publicado: (2004)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

MKlp2 inhibitior paprotrain affects polar body extrusion during mouse oocyte maturation
por: Liu, Jun, et al.
Publicado: (2013)

Thrombotic Thrombocytopenic Purpura Induced by Immune Checkpoint Inhibitiors: A Case Report and Review of the Literature
por: Ali, Zeeshan, et al.
Publicado: (2020)

The Maintenance of Memory Plasma Cells
por: Khodadadi, Laleh, et al.
Publicado: (2019)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013)

Characterization of kidney infiltrating T cells in the NZB/W F1 lupus model
por: Enghard, P, et al.
Publicado: (2004)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
por: Schlesser, Camille, et al.
Publicado: (2022)

The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity
por: Medgyesi, David, et al.
Publicado: (2014)

Stromal Cell-Contact Dependent PI3K and APRIL Induced NF-κB Signaling Prevent Mitochondrial- and ER Stress Induced Death of Memory Plasma Cells
por: Cornelis, Rebecca, et al.
Publicado: (2020)

A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitior
por: Zhang, Chuanfu, et al.
Publicado: (2010)

Antihyperglycemic Effects of Annona diversifolia Safford and Its Acyclic Terpenoids: α-Glucosidase and Selective SGLT1 Inhibitiors
por: Valdés, Miguel, et al.
Publicado: (2020)

Long-term immune reconstitution in patients treated with autologous stem cell transplantation for refractory autoimmune diseases
por: Alexander, T, et al.
Publicado: (2004)

New bortezomib-based combination therapy for elimination of myeloma cells
por: Meister, S, et al.
Publicado: (2009)

Proteasome inhibition by bortezomib: A left hook and a right punch
por: Roelofs, Jeroen
Publicado: (2015)

Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting
por: Penna, Fabio, et al.
Publicado: (2015)

Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
por: Wu, Yi-Xin, et al.
Publicado: (2016)

Type 1 regulatory T cells in treatment of murine lupus
por: Undeutsch, R, et al.
Publicado: (2005)

Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial
por: Astakhova, Tatiana M., et al.
Publicado: (2018)

Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon cancer cell lines via inhibition of the Wnt signaling pathway
por: WU, XUEFANG, et al.
Publicado: (2016)

The ubiquitin–proteasome system as a molecular target in solid tumors: an update on bortezomib
por: Milano, A, et al.
Publicado: (2009)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Hypoxia Enhances the Senescence Effect of Bortezomib—The Proteasome Inhibitor—On Human Skin Fibroblasts
por: Krętowski, Rafał, et al.
Publicado: (2014)

Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
por: Cerruti, Fulvia, et al.
Publicado: (2017)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets
por: Ghansah, Harriet, et al.
Publicado: (2021)

Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome
por: Moreira, Wilfried, et al.
Publicado: (2017)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

B-Lymphozyten und Plasmazellen als Treiber rheumatischer Erkrankungen
por: Hiepe, Falk, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q2h5ficdafedoc0jug3n53efna